Get preferred pricing on the Galleri® multi-cancer early detection test

On this page

Instruction: Change of selection promptly shifts the focus to a matching heading further down, on the same page.

Your exclusive Manulife Vitality Plus offer

We take our commitment to helping Canadians live longer, healthier, better lives seriously. That’s why we’re proud to offer this invaluable discount: 

Eligible Manulife Vitality Plus* members age 50+ get preferred member pricing on the Galleri® multi-cancer early detection test, provided exclusively by Medcan.

Eligible members can enjoy this benefit upon completion of the Vitality Health ReviewTM.

About Medcan

Medcan is a global leader in proactive health and wellness services and is devoted to providing care for individuals, families and employers that is grounded in the latest evidence-based practices, technologies and treatments. Medcan is the official Canadian provider of the Galleri test by GRAIL. The Galleri test by GRAIL sets the standard for multi-cancer early detection and is ideal for those who are seeking a more comprehensive, proactive approach to cancer screening. 

Through a single blood draw, this innovative, clinically validated test screens for 50+ cancer types, like pancreatic and ovarian, before they become symptomatic, maximizing the opportunity for early diagnosis, when treatment can be most effective.

When you choose to do this test, Medcan will be with you every step of the way. Their clinical team will guide you through the testing process and help you navigate your results.

Go to Medcan

Galleri test benefits

Detects a cancer signal in the blood

The test screens your blood sample and identifies DNA fragments shed into the blood by developing cancers.

Increases your chance of detection

Adding the Galleri test to routine cancer screenings can increase your chance of finding cancer by up to seven times.**

Early diagnosis is the most treatable

53% of new cancers diagnosed by the test were stage I or II, when treatment is most effective and there is potential for cure.**

Featured articles

Exciting results revealed

Find out four key highlights of recent studies, which are valuable to understand when you consider taking the test.

See the highlights

Eating these six foods may help you live longer

A global study has shown six foods have helped lower the risk of coronary heart disease, stroke and type 2 diabetes.

More about the study

Can you predict your future health?

Watch a 10-minute video featuring Medcan’s Chief Medical Officer on advanced diagnostics that can help you stay healthier for longer.

Watch the video

Discounted access to the GRAIL Galleri® multi-cancer early detection blood test through Medcan is available to Manulife Vitality Plus™ members who meet specific eligibility criteria.

* To qualify, individuals must be 50 years of age or older, must not have received cancer treatment within the past three (3) years, and have coverage under the following products:

  • Family Term with Vitality Plus™ policy with a total coverage amount of $1,000,000 or greater, excluding rider coverages;
  • Family Term with Vitality™ policy with a total coverage amount of $1,000,000 or greater, excluding rider coverages.
  • Manulife UL with Vitality Plus™ policy with a total coverage amount of $1,000,000 or greater, including coverages from a Term Insurance Rider, but excluding other riders; or
  • Manulife Par with Vitality Plus™ policy with a total coverage amount of $1,000,000 or greater, including coverages from Term Insurance Rider, but excluding other riders.

Manulife Vitality Go™ , Flexcare® and FollowMe™, Health & Dental products are not eligible.

Eligibility for rewards may change over time and are not guaranteed over the full life of the insurance policy.

**The Galleri® multi-cancer early detection blood test does not detect a signal for all cancers. Not all cancers can be detected in the blood. False positive and false negative results do occur. 1 in 100 can expect to receive a CSD result, and approximately 60% of these individuals will receive a confirmed cancer diagnosis. The overall sensitivity in study participants with head and neck cancer was 85.7% (63.2% for stage I, 82.4% stage II, 84.2% stage III, 96.0% stage IV).

The Galleri® multi-cancer early detection blood test is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. The Galleri® test is not a genetic risk assessment and does not predict future genetic risk for cancer. The Galleri® test does not detect a signal for all cancers, and not all cancers can be detected in the blood. False positive and false/negative results do occur. Galleri® should be used in addition to healthcare provider recommended screening tests.

Important Safety Information: The Galleri® test is recommended for use in adults with an elevated risk for cancer, such as those age 50 or older. The test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. The Galleri® test is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of the test is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Lab / Test information: GRAIL, Inc.’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri® test was developed, and its performance characteristics were determined by GRAIL. The Galleri® test has not been cleared or approved by the Food and Drug Administration. This test is not Health Canada or FDA approved and has not been endorsed by any professional medical societies at this time. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri® test is intended for clinical purposes.